Glenn Saldanha
Chairman & Managing Director

glenmark
A new way for a new world

April 5, 2021

To,
The Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

Dear Sir,

Subject: Disclosure under Regulation 30(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011

Enclosed please find herewith the disclosures in terms of Regulation 30(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011 for your information and record.

Thanking you,

Yours Faithfully,

Glenn Saldanha
Authorised Signatory

CC: Glenmark Pharmaceuticals Limited
B/2, Mahalaxmi Chambers,
22, Bhulabhai Desai Road, Mumbai: 400 026

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	GLENMARK PHARMACEUTICALS LIMITED		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED		
3. Particulars of the shareholder(s): a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	AS PER ANNEXURE		
4. Particulars of the Shareholding of persons mentioned at (3) above	Number of Shares	% w.r.t .total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	13,15,67,217	46.63%	-
Total	13,15,67,217	46.63%	-

Part-B**

Name of the Target Company: Glenmark Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/ Promoter group	PAN of the person and PACs
AS PER ANNEXURE	AS PER ANNEXURE	AS PER ANNEXURE

Signature of the Authorised Signatory

Place: Mumbai

Date: 05/04/2021

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	GLENMARK PHARMACEUTICALS LIMITED		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED		
3. Particulars of the shareholder(s): a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	GLENN MARIO SALDANHA		
4. Particulars of the Shareholding of persons mentioned at (3) above	Number of Shares	% w.r.t .total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	9,55,169	0.34%	-
Total	9,55,169	0.34%	-

Part-B**

Name of the Target Company: Glenmark Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	**Whether the person belongs to Promoter/ Promoter group**
GLENN MARIO SALDANHA	YES

Signature of the Authorised Signatory

Place: Mumbai

Date: 05/04/2021

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	GLENMARK PHARMACEUTICALS LIMITED		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED		
3. Particulars of the shareholder(s): a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	SALDANHA FAMILY TRUST		
4. Particulars of the Shareholding of persons mentioned at (3) above	Number of Shares	% w.r.t .total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	12,82,41,936	45.45%	-
Total	12,82,41,936	45.45%	-

B.R.S

Part-B**

Name of the Target Company: Glenmark Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	**Whether the person belongs to Promoter/ Promoter group**
SALDANHA FAMILY TRUST	YES

B. R Saldanha

Signature of the Authorised Signatory

Place: Mumbai

Date: 05/04/2021

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	GLENMARK PHARMACEUTICALS LIMITED		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE LIMITED NATIONAL STOCK EXCHANGE OF INDIA LIMITED		
3. Particulars of the shareholder(s): a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	BLANCHE E SALDANHA		
4. Particulars of the Shareholding of persons mentioned at (3) above	Number of Shares	% w.r.t .total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	11,10,327	0.39%	-
Total	11,10,327	0.39%	-

Part-B**

Name of the Target Company: Glenmark Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/ Promoter group
BLANCHE E SALDANHA	YES

B. E. Saldanha

Signature of the Authorised Signatory

Place: Mumbai

Date: 05/04/2021

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	GLENMARK PHARMACEUTICALS LIMITED		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED		
3. Particulars of the shareholder(s): a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	CHERYLANN MARIA PINTO		
4. Particulars of the Shareholding of persons mentioned at (3) above	Number of Shares	% w.r.t .total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	7,56,535	0.27%	-
Total	7,56,535	0.27%	-

Part-B**

Name of the Target Company: Glenmark Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/ Promoter group
CHERYLANN MARIA PINTO	YES

Signature of the Authorised Signatory

Place: Mumbai

Date: 05/04/2021

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	GLENMARK PHARMACEUTICALS LIMITED		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED		
3. Particulars of the shareholder(s): a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	NEHA SALDANHA		
4. Particulars of the Shareholding of persons mentioned at (3) above	Number of Shares	% w.r.t .total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	6,000	0.00%	-
Total	6,000	0.00%	-

Part-B**

Name of the Target Company: Glenmark Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/ Promoter group
NEHA SALDANHA	YES

Signature of the Authorised Signatory

Place: Mumbai

Date: 05/04/2021

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

Format for Disclosures under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

1. Name of the Target Company (TC)	GLENMARK PHARMACEUTICALS LIMITED		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED		
3. Particulars of the shareholder(s): a. Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the target company) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and Persons Acting in Concert (PAC) with him.	ROBIN JOSEPH PINTO		
4. Particulars of the Shareholding of persons mentioned at (3) above	Number of Shares	% w.r.t .total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of: a) Shares b) Voting Rights (otherwise than by shares) c) Warrants, d) Convertible Securities e) Any other instrument that would entitle the holder to receive shares in the TC.	4,97,250	0.18%	-
Total	4,97,250	0.18%	-

Part-B**

Name of the Target Company: Glenmark Pharmaceuticals Limited

Name(s) of the person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/ Promoter group
ROBIN JOSEPH PINTO	YES



Signature of the Authorised Signatory

Place: Mumbai

Date: 05/04/2021

Note:

1. In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.